U.S. markets closed
  • S&P Futures

    4,207.00
    -16.00 (-0.38%)
     
  • Dow Futures

    33,889.00
    -128.00 (-0.38%)
     
  • Nasdaq Futures

    13,909.00
    -72.25 (-0.52%)
     
  • Russell 2000 Futures

    2,298.60
    -11.50 (-0.50%)
     
  • Crude Oil

    71.66
    -0.49 (-0.68%)
     
  • Gold

    1,824.30
    -37.10 (-1.99%)
     
  • Silver

    27.19
    -0.62 (-2.24%)
     
  • EUR/USD

    1.2008
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.5690
    +0.0700 (+4.67%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.3994
    +0.0007 (+0.05%)
     
  • USD/JPY

    110.6630
    +0.0500 (+0.05%)
     
  • BTC-USD

    38,869.18
    -1,112.66 (-2.78%)
     
  • CMC Crypto 200

    967.20
    -25.27 (-2.55%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    28,906.75
    -384.26 (-1.31%)
     

Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of their COVID-19 vaccine, raising hopes it could join the fight against the pandemic.

  • The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

  • The experimental vaccine "achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers," it said in a statement.

  • "A global pivotal Phase 3 study is expected to start in the coming weeks."

  • The Phase 2 interim results showed 95% to 100% seroconversion following the second injection in all age groups (18 to 95 years old) across all doses, with acceptable tolerability and no safety concerns.

  • A single dose generated high neutralizing antibody levels in participants with evidence of prior SARS-CoV-2 infection, suggesting strong potential for development as a booster vaccine.

  • The company plans to initiate a global Phase 3 study with the 10µg dose in more than 35,000 adult participants.

  • It will assess the efficacy of two vaccine formulations, including the D614 (Wuhan) and B.1.351 (South African) variants.

  • In parallel, the companies intend to conduct booster studies with various variant formulations to assess if a lower vaccine dose generates a strong booster response regardless of the initial vaccine platform received.

  • The vaccine's approval is expected in the fourth quarter of 2021, subject to regulations and Phase 3 outcome.

  • Price Action: GSK shares are down 0.15% at $39.02, and SNY shares are up 0.42% are at $52.96 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.